Molecular markers of systemic therapy response in urothelial carcinoma

doi:10.1016/j.ajur.2021.05.001

摘要
图/表
参考文献
相关文章
推荐阅读
Metrics

下载:

HTML

PDF (484KB)
输出: BibTeX | EndNote (RIS)

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	（）
	作者相关文章

Abstract:

Identification of reliable molecular biomarkers that can complement clinical practice represents a fascinating challenge in any cancer field. Urothelial carcinoma is a very heterogeneous disease and responses to systemic therapies, and outcomes after radical cystectomy are difficult to predict. Advances in molecular biology such as next generation sequencing and whole genome or transcriptomic analysis provide promising platforms to achieve a full understanding of the biology behind the disease and can identify emerging predictive biomarkers. Moreover, the ability to categorize patients' risk of recurrence after curative treatment, or even predict benefit from a conventional or targeted therapies, represents a compelling challenge that may reshape both selection for tailored treatment and disease monitoring. Progress has been made but currently no molecular biomarkers are used in the clinical setting to predict response to systemic agents in either neoadjuvant or adjuvant settings highlighting a relevant unmet need. Here, we aim to present the emerging role of molecular biomarkers in predicting response to systemic agents in urothelial carcinoma.

Key words: Urothelial carcinoma Biomarkers Neoadjuvant chemotherapy Adjuvant chemotherapy Targeted therapies Precision oncology

收稿日期: 2020-09-10 修回日期: 2021-01-07 接受日期: 2021-03-04 出版日期: 2021-10-20 发布日期: 2021-11-08 整期出版日期: 2021-10-20

引用本文:

. [J]. Asian Journal of Urology, 2021, 8(4): 376-390.
Francesco Claps,Maria Carmen Mir,Homayoun Zargar. Molecular markers of systemic therapy response in urothelial carcinoma. Asian Journal of Urology, 2021, 8(4): 376-390.

链接本文:

http://www.ajurology.com/CN/10.1016/j.ajur.2021.05.001 或 http://www.ajurology.com/CN/Y2021/V8/I4/376

Biomarker	Cohort	Source	Setting	Systemic therapy	Summary
DDR genes alterations
ERCC2	50	Tissue	NAC	Cisplatin-based	ERCC2 mutations correlate with pCR at RC [24].
	48	Tissue	NAC	Cisplatin-based	ERCC2 alterations confer vulnerability to cisplatin traducing in better OS [25].
	32	Tissue	NAC	Gem-Cis	Deleterious ERCC2 alterations strongly predicted pDS and superior RFS [26].
ATM	34	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	ATM mutations predicted pCR and better OS/PFS in both sets [27].
ATM	24	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	ATM mutations predicted better OS/DSS in both sets [28].
RB1	34	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	RB1 mutations predicted pCR and better OS/PFS in both sets [27].
RB1	24	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	RB1 mutations predicted better OS/DSS in both sets [28].
FANCC	34	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	FANCC mutations predicted pCR and better OS/PFS in both sets [27].
FANCC	24	Tissue	NAC	MVAC (discovery), Gem-Cis (validation)	FANCC mutations predicted better OS/DSS in both sets [28].
Driver mutations
ERBB2	71	Tissue	NAC	MVAC, Gem-Cis/Car (discovery/validation)	ERBB2 missense mutations predicted pCR and better CSS [33].
ERBB2	52	Tissue	NAC	Gem-Cis	ERBB2 mutations were correlated with pDS [34].
FGFR3	52	Tissue	NAC	Gem-Cis	FGFR3 mutations were correlated with pDS [34].
	72	Tissue	NAC	Gem-Cis	FGFR3 alterations were correlated with pNR and with worse RFS [36].
	74	Tissue	AC	Gem-Cis	FGFR3 alterations were associated with worse RFS [36].
PIK3Ca	52	Tissue	NAC	Gem-Cis	PIK3Ca mutations were correlated with pDS [34].
HUS1	23	Tissue	NAC	Gem-Cis	Amplification of HUS1 predicted pNR and worse RFS [37].
ABCA13	23	Tissue	NAC	Gem-Cis	Amplification of ABCA13 predicted pNR and worse RFS [37].
EGFR	23	Tissue	NAC	Gem-Cis	Amplification of EGFR predicted pNR and worse RFS [37].
FIGNL1	23	Tissue	NAC	Gem-Cis	Amplification of FIGNL1 predicted pNR and worse RFS [37].
IKZF1	23	Tissue	NAC	Gem-Cis	Amplification of IKZF1 predicted pNR and worse RFS [37].
Liquid biopsy
CTCs	20	Blood	NAC	MVAC or Gem-Cis	Patients with medium/high (cut-off 10 CTCs) count showed pNR [58].
CTCs	31	Blood	Metastatic	MVAC	Patients with favorable CTCs trend showed better PFS and OS rates [59].
ctDNA	68	Plasma	NAC/AC	Gem-Cis/Car; Car-Eto; Gem	Dynamics of ctDNA was associated with RFS and OS but not with pDS [70].
ctDNA	17	Plasma	NAC	Cisplatin-based	Persistence of ctDNA detection during NAC predicted disease recurrence [72].
ctDNA	NA	Urine	NAC	Cisplatin-based
miRs
miR-886-3p	30	Tissue	AC/metastatic	MVAC or Gem-Cis	miR-886-3p was correlated with CR (RECIST) and better OS [76].
miR-923	30	Tissue	AC/metastatic	MVAC or Gem-Cis	miR-923 was correlated with CR (RECIST) and better OS [76].
miR-944	30	Tissue	AC/metastatic	MVAC or Gem-Cis	miR-944 was correlated with CR (RECIST) and better OS [76].
miR-138	30	Tissue	AC/metastatic	MVAC or Gem-Cis	Decreasing miR-138 increased the in vitro Cis-sensitivity [76].
miR-27a	30	Tissue	AC/metastatic and in-vitro analysis	MVAC or Gem-Cis	miR-27a overexpression increased the in vitro Cis-sensitivity [76].
miR-27a	354	Tissue		Cisplatin-based	miR-27a increased the in vitro Cis-sensitivity through SLC7A11 axis [77].
miR-642	30	Tissue	AC/metastatic	MVAC or Gem-Cis	miR-642 overexpression increased the in vitro Cis-sensitivity [76].
miR-101	NR	Tissue	In-vitro analysis	Cisplatin-based	miR-101 downregulation induced Cis-resistance through COX-2 axis [78].
miR-193a-3p	NR	Tissue	In-vitro analysis and in-vivo analysis	Cis, Pa, Ad, Epi	miR-193a-3p promotes the multi-chemoresistance [114].
miR-203	108	Tissue	AC	MVAC or Gem-Cis	Low miR-203 expression was correlated with worse PFS and OS [115].
miR-372	83	Tissue	Metastatic	MVAC or Gem-Cis	High miR-372 expression was associated with worse PFS [79].
miR-21	83	Tissue	Metastatic	MVAC or Gem-Cis	High miR-21 expression was associated with a shorter PFS [79].
miR-34a	20	Tissue	NAC and in-vitro analysis	Cisplatin-based or Epi	Increased miR-34a expression mediated in-vitro Cis-sensitivity [116].
miR-34a	20	Tissue	NAC and in-vitro analysis	Cisplatin-based or Epi	miR-34a overexpression resulted in increased in-vitro Epi-sensitivity [117].
miR-101-3p	89	Tissue	In-vitro	Gem-Cis	miR-101-3p overexpression increased chemosensitivity through EZH2 [80].
Cdr1as	NR	Tissue	In-vitro	Cisplatin-based	Cdr1as increased Cis-sensitivity through miR-1270/APAF1 axis [81].

[1]	Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the Nation on the status of cancer, part I: National cancer statistics. Cancer 2018; 124:2785e800.
[2]	Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017; 71:96e108.
[3]	van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009; 56:430e42.
[4]	Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859e66.
[5]	Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. Oncol 2016; 21:708e15.
[6]	Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. Final pathological stage after neo-adjuvant chemotherapy and radical cystectomy for bladder cancerddoes pT0 predict better survival than pTa/Tis/T1? J Urol 2016; 195:886e93.
[7]	Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, et al. Stage pT0 at radical cystectomy con-fers improved survival: An international study of 4,430 pa-tients. J Urol 2010; 184:888e94.
[8]	Grifﬁths G. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171e7.
[9]	Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur Urol 2015; 67:165e70.
[10]	Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int 2014;113:e17e21 https://doi.org/10.1111/bju.12274.
[11]	Grossman HB, Bellmunt J, Black PC. Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer? Eur Urol Oncol 2019; 2:597e602.
[12]	Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol 2016; 34:825e32.
[13]	Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, et al. Cigarette smoking is associated with adverse pathological response and increased disease recur-rence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: A single-centre experience. BJU Int 2019; 123:1011e9.
[14]	Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol Semin Orig Investig 2020;38:3.e17e27. https://doi.org/10.1016/j.urolonc.2019.09.023.
[15]	Claps F, Pavan N, Umari P, Rizzo M, Barbone F, Giangreco M, et al. Incidence, predictive factors and survival outcomes of incidental prostate cancer in patients who underwent radical cystectomy for bladder cancer. Minerva Urol Nefrol 2021;73: 349e56.[16] Zargar H, Almassi N, Kovac E, Ercole C, Remer E, Rinid B, et al. Change in psoas muscle volume as a predictor of out-comes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer. Bladder Cancer 2017; 3:57e63.
[17]	Kaimakliotis HZ, Monn MF, Cho JS, Pedrosa JA, Hahn NM, Albany C, et al. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. Future Oncol 2016; 12:1795e804.
[18]	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Canc 2009; 45:228e47.
[19]	Yoshida T, Kates M, Fujita K, Bivalacqua TJ, Mcconkey DJ. Predictive biomarkers for drug response in bladder cancer. Int J Urol 2019; 26:1044e53.
[20]	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance 2011; 31:1869e83.
[21]	Mouw KW. DNA repair pathway alterations in bladder cancer. Cancers 2017;9:28. https://doi.org/10.3390/cancers9040028.
[22]	Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegﬁlgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32:1889e94.
[23]	Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18:522e8.
[24]	Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Canc Discov 2014; 4:1140e53.
[25]	Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Allen E Van, et al. Clinical validation of chemo-therapy response biomarker ERCC2 in muscle-invasive uro-thelial bladder carcinoma. JAMA Oncol 2016; 2:1094e6.
[26]	Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Machele Donat S, et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol 2018; 36:1949e56.
[27]	Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 2015; 68:959e67.
[28]	Miron B, Hoffman-Censits JH, Anari F, O’Neill J, Geynisman DM, Zibelman MR, et al. Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol Oncol 2020; 3:544e7.
[29]	Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, et al. Whole-exome sequencing of muscle-invasive bladder cancer identiﬁes recurrent mutations of UNC5C and prog-nostic importance of DNA repair gene mutations on survival. Clin Canc Res 2014; 20:6605e17.
[30]	Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical beneﬁt from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 2018; 36:1685e94.
[31]	Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on out-comes. Eur Urol 2018; 73:751e9.
[32]	Geynisman DM, Abbosh P, Zibelman MR, Feldman R, McConkey DJ, Hahn NM, et al. A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neo-adjuvant accelerated MVAC. J Clin Oncol 2018;36:TPS537 https://doi.org/10.1200/jco.2018.36.6_suppl.tps537.
[33]	Groenendijk FH, De Jong J, Fransen Van De Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016; 69:384e8.
[34]	Yang Z, Zhang R, Ge Y, Qin X, Kang X, Wang Y, et al. Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemo-therapy. EBioMedicine 2018; 35:198e203.
[35]	Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB al-terations. J Clin Oncol 2016; 34:2165e71.
[36]	Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, et al. Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothe-lial carcinoma. Eur Urol 2020; 78:907e15.
[37]	Pichler R, Lindner AK, Compérat E, Obrist P, Schäfer G, Todenhöfer T, et al. Ampliﬁcation of 7p12 is associated with pathologic nonresponse to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Am J Pathol 2020; 190:442e52.
[38]	Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer. Clin Canc Res 2021; 27:2435e41.
[39]	Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular character-ization of urothelial bladder carcinoma. Nature 2014; 507:315e22.
[40]	Damrauer JS, Hoadley KA, Chism DD, Fan C, Tignanelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer re?ect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014; 111:3110e5.
[41]	Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identiﬁcation of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Canc Cell 2014; 25:152e65.
[42]	Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classiﬁcation of urothelial carcinoma: Global mRNA classiﬁ-cation versus tumour-cell phenotype classiﬁcation. J Pathol 2017; 242:113e25.
[43]	Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classiﬁcation of muscle-invasive bladder cancer. Eur Urol 2020; 77:420e33.
[44]	Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, et al. Bladder cancer molecular taxonomy: Summary from a consensus meeting. Bladder Cancer 2016; 2:37e47.
[45]	McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, et al. A prognostic gene expression signature in the molec-ular classiﬁcation of chemotherapy-naı¨ve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemo-therapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 2016; 69:855e62.
[46]	Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and sur-vival after neoadjuvant chemotherapy. Eur Urol 2017; 72:544e54.
[47]	Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, et al. Claudin-low bladder tumors are immune inﬁltrated and actively immune suppressed. JCI Insight 2016;1:e85902. https://doi.org/10.1172/jci.insight.85902.
[48]	Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, et al. Validation of a neuroendocrine-like classiﬁer conﬁrms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol 2020; 38:262e8.
[49]	Hensley PJ, Kyprianou N, Purdom MS, He D, DiCarlo V, Wang C, et al. Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urol Oncol 2019;37:572.e1e11. https://doi.org/10.1016/j.urolonc.2019.06.020.
[50]	García-Casas A, García-Olmo DC, García-Olmo D. Further the liquid biopsy: Gathering pieces of the puzzle of genometa-stasis theory. World J Clin Oncol 2017; 8:378e88.
[51]	Contreras-Sanz A, Roberts ME, Seiler R, Black PC. Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. Int J Urol 2017; 24:7e15.
[52]	Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med 2015; 7:1e11.
[53]	Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, et al. Combined transcriptome and genome anal-ysis of single micrometastatic cells. Nat Biotechnol 2002; 20:387e92.
[54]	Zhao C, Hu S, Huo X, Zhang Y. Dr.seq2: A quality control and analysis pipeline for parallel single cell transcriptome and epigenome data. PloS One 2017;12:e0180583. https://doi.org/10.1371/journal.pone.0180583.
[55]	de Kruijff IE, Beije N, Martens JWM, de Wit R, Boormans JL, Sleijfer S. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: A system-atic review. Eur Urol Oncol 2021; 4:204e14.
[56]	Rink M, Chun FKH, Minner S, Friedrich M, Mauermann O, Heinzer H, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 2011; 107:1668e75.
[57]	Winters B, James A, Lee J, Kho J, Morrissey C, Wright J. Chemotherapeutic effects on circulating tumor cells in bladder cancer. Int J Urol 2015; 22:612e3.
[58]	Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, et al. Circulating tumor cells as potential bio-markers in bladder cancer. J Urol 2015; 194:790e8.
[59]	Fina E, Necchi A, Giannatempo P, Colecchia M, Raggi D, Daidone MG, et al. Clinical signiﬁcance of early changes in circulating tumor cells from patients receiving ﬁrst-line cisplatin-based chemotherapy for metastatic urothelial car-cinoma. Bladder Cancer 2016; 2:395e403.
[60]	Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol Semin Orig Investig 2012; 30:44e8.
[61]	Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, et al. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Canc 2017; 140:381e9.
[62]	Roth C, Pantel K, Müller V, Rack B, Kasimir-Bauer S, Janni W, et al. Apoptosis-related deregulation of proteo-lytic activities and high serum levels of circulating nucle-osomes and DNA in blood correlate with breast cancer progression. BMC Canc 2011;11. https://doi.org/10.1186/1471-2407-11-4.
[63]	Gezer U, Holdenrieder S. Post-translational histone modiﬁ-cations in circulating nucleosomes as new biomarkers in colorectal cancer. In Vivo 2014; 28:287e92.
[64]	Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133 https://doi.org/10.1126/scitranslmed. aab0021.
[65]	Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Canc 2011; 11:426e37.
[66]	Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 2016; 70:75e82.
[67]	Teo MTW, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, et al. Next-generation sequencing identiﬁes germline MRE11A variants as markers of radiotherapy out-comes in muscle-invasive bladder cancer. Ann Oncol 2014; 25:877e83.
[68]	Abbosh PH, Rosenberg JE, Plimack ER. Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urol Oncol 2016; 34:502e9.
[69]	Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic proﬁling of circulating tumor DNA. Cancer 2018; 124:2115e24.
[70]	Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of therapeutic efﬁcacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019; 37:1547e57.
[71]	Birkenkamp-Demtröder K, Christensen E, Nordentoft I, Knudsen M, Taber A, Høyer S, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol 2018; 73:535e40.
[72]	Patel KM, Van Der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, et al. Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer. Sci Rep 2017;7:5554. https://doi.org/10.1038/s41598-017-05623-3.
[73]	Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136:642e55.
[74]	Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774:1e20.
[75]	Enokida H, Yoshino H, Matsushita R, Nakagawa M. The role of microRNAs in bladder cancer. Investig Clin Urol 2016;57: S60e76. https://doi.org/10.4111/icu.2016.57.S1.S60.
[76]	Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, et al. MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genom 2012;5:40. https://doi.org/10.1186/1755-8794-5-40.
[77]	Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, et al. Reduced expression of miRNA-27a modu-lates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Canc Res 2014; 20:1990e2000.
[78]	Bu Q, Fang Y, Cao Y, Chen Q, Liu Y. Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. Mol Med Rep 2014; 10:2203e9.
[79]	Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, et al. Association of tumour microRNA proﬁling with outcomes in patients with advanced urothelial carcinoma receiving ﬁrst-line platinum-based chemotherapy. Br J Canc 2016; 115:12e9.
[80]	Li B, Xie D, Zhang H. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J Canc 2019; 10:2628e34.
[81]	Yuan W, Zhou R, Wang J, Han J, Yang X, Yu H, et al. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upre-gulating APAF1 expression through miR-1270 inhibition. Mol Oncol 2019; 13:1559e76.
[82]	Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495:333e8.
[83]	Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47:199e208.
[84]	Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 2014; 281:1750e8.
[85]	Dudek AM, van Kampen JGM, Witjes JA, Kiemeney LALM, Verhaegh GW. LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. Cancer Med 2018; 7:3342e50.
[86]	Krabbe LM, Margulis V, Schrader AJ, Shariat SF, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. World J Urol 2018; 36:1749e57.
[87]	Bellmunt J, Powles T, Vogelzang NJ. A review on the evolu-tion of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Canc Treat Rev 2017; 54:58e67.
[88]	Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in pa-tients with locally advanced and metastatic urothelial car-cinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909e20.
[89]	Galsky M, Saci A, Szabo PM, Han GC, Grossfeld GD, Collette S, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: Efﬁcacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin Canc Res 2021; 26:5120e8.
[90]	Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as ﬁrst-line treatment in cisplatin-ineligible patients with locally advanced and met-astatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 2017; 389:67e76.
[91]	Suzman DL, Agrawal S, Ning Y, Maher VE, Fernandes LL, Karuri S, et al. FDA Approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncol 2019; 24:563e9.
[92]	Tan WP, Tan WS, Inman BA. PD-L1/PD-1 biomarker for met-astatic urothelial cancer that progress post-platinum ther-apy: A systematic review and meta-analysis. Bladder Cancer 2019; 5:211e23.
[93]	Braun DA, Burke KP, Van Allen EM. Genomic approaches to understanding response and resistance to immunotherapy. Clin Canc Res 2016; 22:5642e50.
[94]	Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Canc Therapeut 2017; 16:2598e608.
[95]	Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227e42.
[96]	Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34 https://doi.org/10.1186/s13073-017-0424-2.
[97]	Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391:748e57.
[98]	Iyer NG, Özdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23:4225e31.
[99]	Zhu G, Pei L, Li Y, Gou X. EP300 mutation is associated with tumor mutation burden and promotes antitumor im-munity in bladder cancer patients. Aging (Albany NY) 2020; 12:2132e41.
[100]	Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, et al. Germline genetic polymorphisms in?uence tumor gene expression and immune cell inﬁltration. Proc Natl Acad Sci U S A 2018;115:e11701e10. https://doi.org/10.1073/pnas.1804506115.
[101]	Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study. J Clin Oncol 2018; 36:3353e60.
[102]	Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efﬁcacy and biomarker analysis of neoadjuvant atezolizumab in operable urothe-lial carcinoma in the ABACUS trial. Nat Med 2019; 25:1706e14.
[103]	Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Canc 2016;16:744. https://doi.org/10.1186/s12885-016-2758-3.
[104]	Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carci-noma after platinum therapy (CheckMate 275): A multi-centre, single-arm, phase 2 trial. Lancet Oncol 2017; 18:312e22.
[105]	Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durva-lumab. Clin Canc Res 2018; 24:6212e22.
[106]	Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat Rev Canc 2010; 10:116e29.
[107]	Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, et al. Efﬁcacy of BGJ398, a ﬁbroblast growth factor receptor 1e3 inhibitor, in patients with pre-viously treated advanced urothelial carcinoma with FGFR3 alterations. Canc Discov 2018; 8:812e21.
[108]	Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, et al. Inﬁgratinib in upper tract urothelial car-cinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic proﬁling and/or cell-free DNA results. Cancer 2020; 126:2597e606.
[109]	Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20:1454e66.
[110]	Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdaﬁtinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381:338e48.
[111]	Markham A. Erdaﬁtinib: First global approval. Drugs 2019; 79:1017e21.
[112]	Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019; 37:2592e600.
[113]	Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Canc Res 2016; 76:3003e13.
[114]	Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, et al. The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015; 1852:520e8.
[115]	Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z, et al. MicroRNA-203 is a prognostic indicator in bladder cancer and enhances chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and Survivin. PloS One 2015;10:e0143441. https://doi.org/10.1371/journal.pone.0143441.
[116]	Vinall RL, Ripoll AZ, Wang S, Pan CX, Devere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treat-ment regardless of p53-Rb pathway status. Int J Canc 2012; 130:2526e38.
[117]	Liu X, Liu X, Wu Y, Fang Z, Wu Q, Wu C, et al. MicroRNA-34a attenuates metastasis and chemoresistance of bladder can-cer cells by targeting the TCF1/LEF1 axis. Cell Physiol Bio-chem 2018; 48:87e98.
[118]	Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395:1547e57.

No related articles found!

No Suggested Reading articles found!

Viewed

Full text

Abstract

Cited

Shared

Discussed